Paclitaxel for non-small cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 8, 2004, Pages 1771-1780

  Ramalingam, Sakkaraiappan ^b   Belani, Chandra P ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Lung cancer; NSCLC; Paclitaxel; Taxane

Indexed keywords

ALCOHOL; ANALGESIC AGENT; ANTIBIOTIC AGENT; BETA TUBULIN; BEVACIZUMAB; CARBOPLATIN; CASTOR OIL; CETUXIMAB; CISPLATIN; CREMOPHOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETOPOSIDE; GEFITINIB; GEMCITABINE; MATUZUMAB; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; PANITUMUMAB; PLATINUM DERIVATIVE; POLYGLUTAMIC ACID PACLITAXEL; PROTEIN SUBUNIT; PROTEIN TYROSINE KINASE; TAXANE DERIVATIVE; TENIPOSIDE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEBRILE NEUTROPENIA; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MYALGIA; NAUSEA; NEUROPATHY; PERIPHERAL NEUROPATHY; REVIEW; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; PACLITAXEL; POLYETHYLENE GLYCOLS; VEHICLES;

EID: 4344564184     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.8.1771     Document Type: Review

References (75)

1. JEMAL A, TIWARI RC, MURRAY T et al.: Cancer statistics, 2004. CA Cancer J. Clin. (2004) 54:8-29.
2. SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. (2002) 346:92-98.
3. CURRAN W, SCOTT C, LANGER CJ et al.: Phase III comparison of sequential versus concurrent chemoradiation for patients (Pts) with unresected Stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc. Am. Soc. Clin. Oncol. (2000) 19:484a.
4. BELANI CP, NATALE RB, LEE JS et al.: Randomized Phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1998) 17:455a.
5. ARRIAGADA R, BERGMAN B, DUNANT A, LE CHEVALIER T, PIGNON JP, VANSTEENKISTE J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med (2004) 350:351-360.
6. DILLMAN RO, SEAGREN SL, PROPERT KJ et al.: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N. Engl. J. Med. (1990) 323:940-945.
7. LE CHEVALIER T, ARRIAGADA R, QUOIX E et al.: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl. Cancer Inst. (1991) 83:417-423.
8. KATO H, ICHINOSE Y, OHTA M et al.: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J Med. (2004) 350:1713-1721.
9. LILENBAUM RC, HERNDON JE 2nd, LIST M et al.: Single agent versus combination chemotherapy in patients with advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. Proc. Am. Soc. Clin. Oncol. (2002) 21:1a (Abstract 2).
10. KELLY K, CROWLEY J, BUNN PA Jr: et al.: Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. (2001) 19:3210-3218.
11. RANSON M, DAVIDSON N, NICOLSON M et al.: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (2000) 92:1074-1080.
12. BONOMI P, KIM K, FAIRCLOUGH D et al.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. (2000) 18:623-631.
13. GIACCONE G, SPLINTER TA, DEBRUYNE C et al.: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. (1998) 16:2133-2141.
14. VOKES EE, HERNDON JE 2nd, CRAWFORD J et al.: Randomized Phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J. Clin. Oncol. (2002) 20:4191-4198.
15. WANI MC, TAYLOR HL, WALL ME, COGGON P, MCPHAIL AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am. Chem. Soc. (1971) 93:2325-2327.
16. EISENHAUER EA, VERMORKEN JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs (1998) 55:5-30.
17. GELDERBLOM H, VERWEIJ J, NOOTER K, SPARREBOOM A: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer (2001) 37:1590-1598.
18. SZEBENI J, MUGGIA FM, ALVING CR: Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. (1998) 90:300-306.
19. LESSER GJ, GROSSMAN SA, ELLER S, ROWINSKY EK: The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother. Pharmacol. (1995) 37:173-178.
20. WINDEBANK AJ, BLEXRUD MD, DE GROEN PC: Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol. Exp. Ther. (1994) 268:1051-1056.
21. GELDERBLOM H, MROSS K, TEN TIJE AJ et al.: Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J. Clin. Oncol. (2002) 20:574-581.
22. ROWINSKY EK, EISENHAUER EA, CHAUDHRY V, ARBUCK SG, DONEHOWER RC: Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. (1993) 20:1-15.
23. CHANG AY, KIM K, GLICK J, ANDERSON T, KARP D, JOHNSON D: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J. Natl. Cancer Inst. (1993) 85:388-394.
24. MURPHY WK, FOSSELLA FV, WINN RJ et al.: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (1993) 85:384-388.
25. GATZEMEIER U, HECKMAYR M, NEUHAUSS R et al.: Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer (1995) 12(Suppl. 2):S101-S106.
26. TESTER WJ, JIN PY, REARDON DH, COHN JB, COHEN MH: Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer (1997) 79:724-729.
27. HAINSWORTH JD, THOMPSON DS, GRECO FA: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J. Clin. Oncol. (1995) 13:1609-1614.
28. KOUMAKIS G, DEMIRI M, BARBOUNIS V et al.: Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a Phase II trial. Lung Cancer (2002) 35:315-317.
29. SOCINSKI MA, SCHELL MJ, BAKRI K et al.: Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer (2002) 95:1265-1273.
30. SCULIER JP, BERGHMANS T, LAFITTE JJ et al.: A Phase II study testing paclitaxel as second-fine single agent treatment for patients with advanced non-small cell lung cancer fading after a first-line chemotherapy. Lung Cancer (2002) 37:73-77.
31. NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. (1995) 311:899-909.
32. RAMALINGAM S, BELANI CP: Taxanes for advanced non-small cell lung cancer. Expert Opin. Pharmacother. (2002) 3:1693-1709.
33. BELANI CP, KEARNS CM, ZUHOWSKI EG et al.: Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin. Oncol. (1999) 17:676-684.
34. BOOKMAN MA, MCGUIRE WP 3rd, KILPATRICK D et al.: Carboplatin and paclitaxel in ovarian carcinoma: a Phase I study of the Gynecologic Oncology Group. J. Clin. Oncol. (1996) 14:1895-902.
35. ROSELL R, GATZEMEIER U, BETTICHER DC et al.: Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann. Oncol. (2002) 13:1539-1549.
36. SMIT EF, VAN MEERBEECK JP, LIANES P et al.: Three-arm randomized study of two cisplatin-based regimens and paditaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J. Clin. Oncol. (2003) 21:3909-3917.
37. KOSMIDIS P, MYLONAKIS N, NICOLAIDES C et al.: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol. (2002) 20:3578-3585.
38. ROSE WC: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. J. Natl. Cancer Inst. Monogr. (1993):47-53.
39. AKERLEY W, CHOY H, SAFRAN H et al.: Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a Phase II trial. Semin. Oncol. (1997) 24(4 Suppl. 12):S12-10-S12-13.
40. AKERLEY W, HERNDON JE, EGORIN MJ et al.: Weekly, high-dose paclitaxel in advanced lung carcinoma: a Phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer (2003) 97:2480-2486.
41. BELANI CP, BARSTIS J, PERRY MC et al.: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J. Clin. Oncol. (2003) 21:2933-2939.
42. KELLY K, PAN Z, MURPHY J, HUFFMAN DH, BUNN PA Jr: A Phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin. Cancer Res. (1997) 3:1117-1123.
43. HUIZING MT, VAN WARMERDAM LJ, ROSING H et al.: Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J. Clin. Oncol. (1997) 15:1953-1964.
44. KOSMIDIS P, MYLONAKIS N, SKARLOS D et al.: Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann. Oncol. (2000) 11:799-805.
45. SAUSE W, KOLESAR P, TAYLOR SI et al.: Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest (2000) 117:358-364.
46. JEREMIC B, SHIBAMOTO Y, ACIMOVIC L, DJURIC L: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J. Clin. Oncol. (1995) 13:452-458.
47. TISHLER RB, SCHIFF PB, GEARD CR, HALL EJ: Taxol: a novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys. (1992) 22:613-617.
48. LEONARD CE, CHAN DC, CHOU TC, KUMAR R, BUNN PA: Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. (1996) 56:5198-204.
49. NIERO A, EMILIANI E, MONTI G et al.: Paclitaxel and radiotherapy- sequence-dependent efficacy-a preclinical model. Clin. Cancer Res. (1999) 5:2213-2222.
50. LAU D, LEIGH B, GANDARA D et al.: Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium Phase II trial. J. Clin. Oncol. (2001) 19:442-447.
51. CHOY H, AKERLEY W. SAFRAN H et al.: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J. Clin. Oncol. (1994) 12:2682-2686.
52. CHOY H, SAFRAN H, AKERLEY W. GRAZIANO SL, BOGART JA, COLE BF: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin. Cancer Res. (1998) 4:1931-1936.
53. CHOY H, AKERLEY W, SAFRAN H et al.: Multiinstitutional Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J. Clin. Oncol. (1998) 16:3316-3322.
54. BELANI CP, AISNER J, BAHRI S et al.: Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. Semin. Oncol. (1996) 23:113-116.
55. GANDARA DR, CHANSKY K, ALBAIN KS et al.: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J. Clin. Oncol. (2003) 21:2004-2010.
56. PANTEL K, IZBICKI JR, ANGSTWURM M et al.: Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res. (1993) 53:1027-1031.
57. PASSLICK B, KUBUSCHOK B, IZBICKI JR, THETTER O, PANTEL K: Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann. Thorac. Surg. (1999) 68:2053-2058.
58. ROTH JA, FOSSELLA F, KOMAKI R et al.: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. (1994) 86:673-680.
59. ROSELL R, GOMEZ-CODINA J, CAMPS C et al.: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. (1994) 330:153-158.
60. PISTERS KM, GINSBERG RJ, GIROUX DJ et al.: Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J. Thorac. Cardiovasc. Surg. (2000) 119:429-439.
61. HOLSINGER FC, DOAN DD, JASSER SA et al.: Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin. Cancer Res. (2003) 9:3183-3189.
62. NGUYEN DM, LORANG D, CHEN GA, STEWART JHT, TABIBI E, SCHRUMP DS: Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann. Thorac. Surg. (2001) 72:371-378; Discussion 378-379.
63. PEGRAM M, HSU S, LEWIS G et al.: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene (1999) 18:2241-2251.
64. CIARDIELLO F, CAPUTO R, DAMIANO V et al.: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. (2003) 9:1546-1556.
65. INOUE K, SLATON JW, PERROTTE, P et al.: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. (2000) 6:4874-4884.
66. KRIS MG, NATALE RB, HERBST RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290:2149-2158.
67. HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III Trial - INTACT 2. J. Clin. Oncol. (2004) 22:785-794.
68. KELLY K, HANNA N, ROSENBERG A, BUNN PA, NEEDLE MN: A multi-centered Phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:644 (Abstract 2592).
69. BOKEMEYER C, KOLLMANNSBERGER C, SCHITTENHELM M: A Phase I study of epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with Paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC). Eur. J. Cancer (2003) I:S20 (Abstract 53).
70. KATO H, TSUBOI M, OHTA M, HATA E, TSUBOTA N: A randomized Phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I adenocarcinoma of the lung. Proc. Am. Soc. Clin. Oncol. (2003) 22:621.
71. SINGER JW, BAKER B, DE VRIES P et al.: Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. (2003) 519:81-99.
72. IBRAHIM NK, DESAI N, LEGHA S et al.: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. (2002) 8:1038-1044.
73. MASTALERZ H, COOK D, FAIRCHILD CR et al.: The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg. Med. Chem. (2003) 11:4315-4323.
74. LANGER C, STEPHENSON P, SCHILLER J, TESTER WJ, RAPOPORT BL: ECOG 1599: Randomized Phase II study of paclitaxel/carboplatin versus cisplatin/gemcitabine in performance status (PS) w patients with treatment-naive advanced NSCLC. Lung Cancer (2003) 41:S18.
75. GATZEMEIER U, VON PAWEL J, GOTTFRIED M et al.: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2000) 18:3390-3399.